GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (NAS:OPT) » Definitions » Cash Receipts from Securities Related Activities

OPT (Opthea) Cash Receipts from Securities Related Activities


View and export this data going back to 2011. Start your Free Trial

What is Opthea Cash Receipts from Securities Related Activities?

Cash Receipts from Securities Related Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Opthea Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (NAS:OPT) » Definitions » Cash Receipts from Securities Related Activities
Traded in Other Exchanges
Address
650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.